INTRODUCTION TO A NEW SERIES: DISPATCHES FROM THE GUILD CONFERENCEDispatches from the GUILD Conference
DISPATCHES FROM THE GUILD CONFERENCE, SERIES #1Practical Use of Therapeutic Drug Monitoring of Anti-TNF Therapy in IBD
Anti-tumor necrosis factor therapy has revolutionized the care of inflammatory bowel disease. However, 10-30% of IBD patients show no initial clinical benefit to anti-TNF therapy and over 50% after an initial response lose response over time. Therapeutic drug monitoring can better explain and guide the management of patients with a loss of response to anti-TNF therapy. This review will focus on the role of TDM in guiding therapeutic decisions in IBD.
NUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #160The Use of Medium-Chain Triglycerides in Gastrointestinal Disorders
Medium-chain triglycerides (MCTs) are lipid molecules that are more readily absorbed and oxidized than most lipids. This unique characteristic of MCTs has led to interest in their use in the management of several gastrointestinal disorders, where MCTs have been primarily used to reduce fat malabsorption and to serve as a source of calories to optimize nutritional status. In this review, we discuss the composition of MCTs, its sources, and the roles that they potentially play in the treatment of various gastrointestinal disorders.
FRONTIERS IN ENDOSCOPY, SERIES #34Endoscopic Management of Large Duodenal Adenomas
Duodenal adenomas are often incidentally detected during routine upper endoscopies, yet data regarding effective management are scarce. With advances in endoscopic tools and techniques, duodenal adenomas are increasingly managed endoscopically. There are two main endoscopic resection techniques: endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD). Compared to EMR during colonoscopy, EMR in the duodenum is much more arduous and complications are more problematic to manage. In this article, all practical points on how best to perform duodenal adenoma resection and data on follow-up are reviewed.
A CASE REPORTNocardiosis in a Patient with Crohn's Disease
TRUESELF™ FOODS LAUNCHES LOW-FODMAP PRODUCTS FOR IBS SUFFERERS
Waccabuc, NY TrueSelf™ Foods has launched their new line of prepared low-FODMAP foods specifcally designed for people who suffer from Functional Gastrointestinal Disorders (FGDs). Founded by Dr. Miechelle O'Brien, M.D, Ph.D., a practicing gastroenterologist, TrueSelf launched its product line with a variety of nutrition bars and plans to expand to other products in 2017.
PIVOTAL PHASE 3 DATA RESULTS FOR TRULANCE™ (PLECANATIDE) IN THE TREATMENT OF CHRONIC IDIOPATHIC CONSTIPATION (CIC) PUBLISHED IN AMERICAN JOURNAL OF GASTROENTEROLOGY
February 2017, NEW YORK - Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced that the American Journal of Gastroenterology has published detailed results from a pivotal Phase 3 trial that demonstrated the ef cacy and safety of TRULANCET™ (plecanatide) for the treatment of adults with chronic idiopathic constipation (CIC).